Episurf Medical AB (EPIS-B) Fair Value & Analysis
Healthcare · SE · Market cap 400M SEK
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 27 days ago
Share price −30.1% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 0.0274 – kr 0.2000 · fair‑value band kr 0.0340 – kr 0.0510 · the kr 0.0605 price screens above the kr 0.0425 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Episurf Medical AB (EPIS-B) currently trades at kr 0.0605, while our model-based Fair Value estimate is kr 0.0425, implying the stock looks roughly 29.8% overvalued today. We read business quality at 31/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at 20.2M SEK. Revenue declined 20.0% year over year. It earns a return on equity of -88.7%. Fundamentals as of Jun 24, 2026
Our scenario range runs from kr 0.0340 (bear case) to kr 0.0510 (bull case); at kr 0.0605, the current price sits above that range. The share trades about 79% below its 52-week high and 147% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -30%, EPIS-B screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Episurf Medical AB reported revenue of kr 13.5M in FY2025 versus kr 6.5M in FY2021, a compound +20.0%/yr. Reported net income was −kr 58.2M in FY2025.
Is EPIS-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $86.97 | $69.36 | -20% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EWL | €75.46 | €37.29 | -51% |
| Siemens Healthineers AG SEMHF | $39.91 | $48.29 | +21% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $61.99 | $48.34 | -22% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
| Koninklijke Philips N.V PHG | $26.98 | $12.54 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Episurf Medical AB (EPIS-B) undervalued?
What is the fair value of EPIS-B?
What is the quality score of EPIS-B?
What is the revenue of Episurf Medical AB (EPIS-B)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Episurf Medical AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.